Table 2 Adverse events occurring in more than one subject in the Dyslipidemia study. No serious adverse events and no discontinuations were identified
From: Specific inhibition of bile acid transport alters plasma lipids and GLP-1
Placebo (N = 12) | A3309 - 2.5 mg (N = 12) | A3309 - 5 mg (N = 12) | ||
|---|---|---|---|---|
MedDRA system organ class | MedDRA preferred term | n (%) | n (%) | n (%) |
Gastrointestinal disorders | Abdominal distension | 1 (8.3) | 1 (8.3) | 1 (8.3) |
Constipation | 4 (33.3) | 1 (8.3) | - | |
Diarrhoea | 3 (25.0) | 2 (16.7) | 3 (25.0) | |
General disorders and administration site conditions | ||||
Pyrexia | 1 (8.3) | - | 1 (8.3) | |
Infections and infestations | ||||
Pharyngitis | 1 (8.3) | - | 1 (8.3) | |
Rhinitis | 2 (16.7) | - | - | |
Musculoskeletal and connective tissue disorders | Myalgia | 2 (16.7) | - | - |
Nervous system disorders | Dizziness | 2 (16.7) | - | - |
Headache | 3 (25.0) | 3 (25.0) | 3 (25.0) | |
Renal and urinary disorders | Polyuria | 1 (8.3) | 1 (8.3) | - |
Respiratory, thoracic and mediastinal disorders | Cough | 1 (8.3) | - | 1 (8.3) |